Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT01889186
Title A Study of the Efficacy of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia With the 17p Deletion
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors AbbVie, Genentech, Inc.
Age Groups: adult
Covered Countries USA | FRA | DEU | CAN

No variant requirements are available.